Monopar Therapeutics Inc. (NASDAQ:MNPR) Short Interest Up 57.8% in February

Monopar Therapeutics Inc. (NASDAQ:MNPRGet Free Report) was the recipient of a large growth in short interest in February. As of February 28th, there was short interest totalling 51,300 shares, a growth of 57.8% from the February 13th total of 32,500 shares. Based on an average daily volume of 66,900 shares, the short-interest ratio is currently 0.8 days. Approximately 1.3% of the shares of the stock are sold short.

Analyst Ratings Changes

MNPR has been the subject of several research reports. HC Wainwright lifted their price objective on Monopar Therapeutics from $22.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, January 22nd. Piper Sandler began coverage on shares of Monopar Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating and a $72.00 price objective for the company.

Read Our Latest Research Report on Monopar Therapeutics

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Point72 Asset Management L.P. purchased a new position in shares of Monopar Therapeutics in the fourth quarter valued at $3,694,000. Janus Henderson Group PLC purchased a new stake in shares of Monopar Therapeutics during the fourth quarter worth about $23,435,000. JPMorgan Chase & Co. acquired a new position in shares of Monopar Therapeutics in the fourth quarter worth about $45,000. Geode Capital Management LLC boosted its holdings in Monopar Therapeutics by 174.4% in the fourth quarter. Geode Capital Management LLC now owns 38,596 shares of the company’s stock valued at $849,000 after purchasing an additional 24,530 shares during the last quarter. Finally, RA Capital Management L.P. purchased a new stake in Monopar Therapeutics during the 4th quarter worth approximately $11,247,000. 1.83% of the stock is owned by hedge funds and other institutional investors.

Monopar Therapeutics Price Performance

MNPR stock traded up $3.19 during midday trading on Monday, hitting $32.94. The stock had a trading volume of 13,869 shares, compared to its average volume of 360,329. Monopar Therapeutics has a 12-month low of $1.72 and a 12-month high of $54.30. The firm has a market cap of $200.97 million, a PE ratio of -16.72 and a beta of 1.18. The company’s 50-day moving average price is $35.77 and its 200 day moving average price is $21.54.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

Further Reading

Receive News & Ratings for Monopar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Monopar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.